Genertec Universal Medical Group Co (2666.HK) Osake Kurssi
Genertec Universal Medical Group Co Kurssi
Viimeisten 13 vuoden aikana Genertec Universal Medical Group Con liikevaihto kasvoi 27,9 % vuodessa ja ylsi 16,93 Mrd. CNY:een. Osakekohtainen tulos on kasvanut 13,2 % vuodessa viimeisten 12 vuoden aikana. Genertec Universal Medical Group Con nettomarginaali 15,2 % on laskenut verrattuna 20,4 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 9,20 %. Jakosuhde on noin 23 % tuloksesta. Osinko on kasvanut 11,6 % vuodessa viimeisten 9 vuoden aikana. Genertec Universal Medical Group Con 12 kuukauden konsensustavoitehinta on 6,96 CNY, noin yli kurssia 82,8 %. 8 analyytikosta 7 suosittaa ostoa — kokonaiskonsensus on Osta.
Genertec Universal Medical Group Co osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Genertec Universal Medical Group Co liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Genertec Universal Medical Group Co -osakkeesta
The business model of Genertec Universal Medical Group Co Ltd is focused on providing comprehensive medical solutions and services. With China as its core market, the company operates various business segments, including medical equipment and instrument manufacturing, medical technology research and development, medical service outsourcing, and medical investment and management. Genertec Universal Medical Group Co Ltd aims to leverage its expertise and resources to promote the development of China's medical industry, enhance healthcare services, and improve overall medical standards.
Genertec Universal Medical Group Co Ltd operates primarily in the healthcare and medical industry. With a focus on providing comprehensive medical services, the company offers a wide range of healthcare solutions including hospital management, medical equipment manufacturing, pharmaceutical research and development, and healthcare technology services. Genertec Universal Medical Group Co Ltd strives to contribute to the advancement of healthcare by delivering innovative and high-quality services to patients.
The main competitors of Genertec Universal Medical Group Co Ltd in the market include Beijing Tiantan Hospital, China National Pharmaceutical Group Corporation, and China Resources (Holdings) Co Ltd.
Genertec Universal Medical Group Co Ltd is a diversified healthcare company based in China. Established in 2001, the company has since grown to become one of the leading providers of medical products and services in the country. With a strong focus on innovation and quality, Genertec Universal Medical Group has continuously expanded its product portfolio and developed strategic partnerships with global medical technology companies. The company's commitment to improving healthcare standards in China has earned it a solid reputation within the industry. With a comprehensive range of medical devices, pharmaceuticals, and healthcare solutions, Genertec Universal Medical Group continues to contribute to the advancement of healthcare in China and beyond.
Some significant milestones achieved by Genertec Universal Medical Group Co Ltd include successful partnerships with leading healthcare organizations, expansion into international markets, and the development of innovative medical technologies. The company has established strategic alliances with renowned medical institutions, enhancing its research and development capabilities. Genertec Universal Medical Group Co Ltd has also experienced positive growth in global markets, reflecting its commitment to delivering high-quality medical products and services worldwide. Additionally, the company has introduced groundbreaking advancements in medical technology, improving patient care and revolutionizing the healthcare industry.
Genertec Universal Medical Group Co Ltd is primarily present in China.
Genertec Universal Medical Group Co Ltd embraces a set of core values and corporate philosophy that defines its operations. As a leading medical services company, Genertec Universal Medical Group Co Ltd prioritizes excellence, patient-centered care, and innovation in the healthcare industry. With a focus on providing high-quality medical services, the company upholds integrity, professionalism, and compassion in all its endeavors. By combining cutting-edge technology and advanced medical expertise, Genertec Universal Medical Group Co Ltd aims to enhance patient outcomes and contribute to the overall advancement of healthcare.
Analyytikot asettavat tällä hetkellä Genertec Universal Medical Group Co-osakkeelle keskimääräisen tavoitehinnan 6,96 CNY (mediaani: 6,96 CNY), mikä merkitsee +82,8 % viimeisimpään hintaan verrattuna. Konsensus perustuu 8 analyytikkoarvioon.
Genertec Universal Medical Group Co Analyytikkojen kursstavoitteet 2026
8 analyytikkoa arvioi tällä hetkellä Genertec Universal Medical Group Co-osaketta: 7 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Genertec Universal Medical Group Co-yhtiöltä 15,17 Mrd. CNY liikevaihtoa ja 1,14 CNY osakekohtaista tulosta.
Genertec Universal Medical Group Co Analyytikkojen kursstavoitteet 2026
Nykyisellä valuuttakurssilla Genertec Universal Medical Group Co-osake noteerataan hintaan 0,51 EUR (3,81 CNY).
Genertec Universal Medical Group Co-osake (2666.HK) on listattuna 3 pörssissä, muun muassa: Hongkong (HKEX) (2666.HK), Frankfurt (5UM.F).
The company Genertec Universal Medical Group Co Ltd (GUMG) is an internationally operating company in the healthcare sector. It was founded in 2001 as a subsidiary of Genertec Holding Co Ltd, one of the leading Chinese energy companies. GUMG's business model is to offer comprehensive healthcare services that encompass all aspects of the healthcare industry. The company consists of various divisions, all contributing to the overall strategy of the healthcare company in different ways. One of GUMG's most important divisions is the hospital group. The company operates multiple hospitals in China and strives to provide high-quality medical services at the highest level. The hospitals offer specialized treatments for cancer patients, cardiovascular diseases, as well as neurology and orthopedics. Another important area of GUMG is research and development. The company has been investing in the research of new drugs and treatment methods for years, collaborating closely with renowned universities and research institutions in China. GUMG has already achieved several significant medical breakthroughs and continues its research activities to further improve healthcare in the future. In addition to hospitals and research, GUMG also heavily invests in the development of medical devices and technologies. The company operates its own research and development team that develops innovative products and brings them to the international market. Some of the products offered by GUMG include ultrasound devices, endoscopy equipment, EKG systems, and other medical instruments. Lastly, GUMG is also heavily involved in the training of medical professionals. The company operates its own training facilities and advocates for the improvement of medical education in China and other countries. GUMG aims to educate a new generation of physicians who are equipped to meet the challenges of modern healthcare. In summary, GUMG's business model is focused on providing comprehensive healthcare services. The company operates hospitals, conducts research and develops new medical products and technologies, and engages in the training of medical professionals. GUMG collaborates closely with universities and research institutions and strives to improve healthcare worldwide.
odotettu liikevaihto Genertec Universal Medical Group Co on 15,17 Mrd. CNY. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Genertec Universal Medical Group Co on 2,31 Mrd. CNY. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Genertec Universal Medical Group Co:n hinta-voitto-suhde (P/E) on tällä hetkellä 3,34. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Genertec Universal Medical Group Co-osakkeen arvostusta.
Genertec Universal Medical Group Co:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,51. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Genertec Universal Medical Group Co-osakkeen arvostuskennuslukuna.
Genertec Universal Medical Group Co:n Eulpool-laatuscore on 5/10.
Genertec Universal Medical Group Co:n ISIN on HK0000255361. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Genertec Universal Medical Group Co:n WKN on A14V3L. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Genertec Universal Medical Group Co:n ticker on 2666.HK. Tämä pörssinoteeraus käytetään Genertec Universal Medical Group Co-osakkeiden kauppaan pörssissä.
Genertec Universal Medical Group Co osake
Genertec Universal Medical Group Co vertaisryhmä
Genertec Universal Medical Group Co Ticker
Genertec Universal Medical Group Co FIGI
Kaikki tunnusluvut ja syvällinen analyysi Genertec Universal Medical Group Co:sta
Meidän osakeanalyysimme Genertec Universal Medical Group Co-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Genertec Universal Medical Group Co:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: